Author Archives: Patricia Inacio PhD

Ibudilast-Rilutek Therapy Combo Closer to U.S. Patent for ALS and Other Neurodegenerative Diseases

MediciNova’s  investigational therapy ibudilast (MN-166) combined with Rilutek (riluzole), for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, has been given final approval — a notice of allowance stating that its request for a patent is being considered by the U.S. Patent and Trademark Office. Receiving a notice of allowance is the final…

Axon-seq Lets Researchers Better Analyze mRNAs in Study of ALS

A new method called Axon-seq allows researchers to analyze the content of messenger RNAs (mRNAs) in the motor neuron’s axons, the tips of the nerve cells that communicate with muscle cells, a new study reports. Using Axon-seq, researchers identified 121 mRNAs that are deregulated in ALS motor neurons, highlighting the new…